


Online Resource 4

Kaplan-Meier overall and median survival by age-specific treatment groups. Adults diagnosed with histologically confirmed glioblastoma at 18–89 years during 2019–2023 (N = 1158).

TMZ = temozolomide.



	Number of patients	Median overall survival, months (95% CI)
Treatment group, 18–70 years		
Resection, ≥ 55 Gy, TMZ	544	16.0 (15.1–16.8)
Biopsy, ≥ 55 Gy, TMZ	27	12.6 (8.3–15.8)
Resection, < 55 Gy or no TMZ	125	9.9 (7.7–12.4)
Biopsy, < 55 Gy or no TMZ	35	6.8 (3.8–10.5)
No anti-neoplastic treatment	47	1.2 (0.9–2.0)
Treatment group, 71–89 years		
≥ 30 Gy, TMZ	249	11.4 (9.8–12.6)
≥ 30 Gy, no TMZ	37	4.5 (3.6–6.2)
< 30 Gy, any TMZ	9	Not estimated
TMZ, no radiation	8	Not estimated
No anti-neoplastic treatment	77	1.8 (1.2–2.6)

Article title: Unveiling regional differences in glioblastoma patient survival with real-world data from the Norwegian brain tumor quality registry

Journal name: Journal of Neuro-Oncology

Author names: Cassia Bree Trewin-Nybråten¹, Paul Christopher Lambert^{1,2}, Kirsten Marienhagen³, Lasse Andreassen⁴, Tom Børge Johannesen¹, Pitt Niehusmann^{5,6}, Leif Oltedal^{7,8}, Stephanie Schipmann^{9,10}, Anne Jarstein Skjulsvik^{11,12}, Ole Solheim^{13,14}, Tora Skeidsvoll Solheim^{12,15}, Terje Sundstrøm^{8,9}, Einar Osland Vik-Mo^{16,17,18}, Petter Brandal^{18,19,20}, Tor Ingebrigtsen^{4,21}, Erlend Skaga^{16,17}

¹ Department of Registration, Cancer Registry of Norway, Norwegian Institute of Public Health, Oslo, Norway (CBT, PCL, TBJ)

² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden (PCL)

³ Department of Oncology, University Hospital of North Norway, Tromsø, Norway (KM)

⁴ Department of Neurosurgery, Otorhinolaryngology and Ophthalmology, University Hospital of North Norway, Tromsø, Norway (LA, TI)

⁵ Department of Pathology, Oslo University Hospital, Oslo, Norway (PN)

⁶ Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway (PN)

⁷ Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland (LO) University Hospital, Bergen, Norway

⁸ Department of Clinical Medicine, University of Bergen, Bergen, Norway (LO, TS)

⁹ Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway (SS, TS)

¹⁰ Department of Neurosurgery, University Hospital Muenster, Germany (SS)

¹¹ Department of Pathology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway (AJS)

¹² Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway (AJS, TSS)

¹³ Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway (OS)

¹⁴ Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway (OS)

¹⁵ Cancer Clinic, St. Olavs University Hospital, Norway (TSS)

¹⁶ Vilhelm Magnus Laboratory for Neurosurgical Research, Oslo University Hospital, Oslo, Norway (EOVM, ES)

¹⁷ Department of Neurosurgery, Oslo University Hospital, Oslo, Norway (EOVM, ES)

¹⁸ Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway (EOVM, PB)

¹⁹ Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway (PB)

²⁰ Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway (PB)

²¹ Department of Clinical Medicine, Faculty of Health Sciences, UiT the Arctic University of Norway, Tromsø, Norway (TI)

Corresponding author: tor.ingebrigtsen@uit.no